Skyrizi and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis. Omvoh gained UC approval first in October 2023 based on LUCENT-1 and LUCENT-2. Skyrizi followed in June 2024 based on INSPIRE and COMMAND. Patients comparing these two within-class UC options often weigh maintenance dosing, bowel urgency outcomes, and trial design. This guide walks through the skyrizi vs omvoh ulcerative colitis comparison.
Same Class, Two Molecules
Skyrizi (risankizumab) and Omvoh (mirikizumab) both bind the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 drives Th17 inflammation central to UC pathology. The risankizumab vs mirikizumab UC distinction is a within-class decision: the structural mechanism is shared, but the molecules differ in affinity, half-life, and the clinical programs that support each.
Trial Evidence: INSPIRE/COMMAND vs LUCENT
Skyrizi's UC approval rests on INSPIRE (induction) and COMMAND (maintenance). INSPIRE showed clinical remission rates of 20.3% on Skyrizi versus 6.2% on placebo at week 12, with endoscopic improvement and symptomatic remission also significantly better. COMMAND showed sustained benefit through week 52. Omvoh's UC approval rests on LUCENT-1 (induction) and LUCENT-2 (maintenance). LUCENT-1 showed clinical remission rates of 24.2% on Omvoh versus 13.3% on placebo at week 12, with endoscopic remission, symptomatic remission, and bowel urgency improvement also significantly better. LUCENT-2 showed 49.9% of Omvoh patients in clinical remission at week 40 versus 25.1% on placebo. The LUCENT vs INSPIRE comparison is informative because LUCENT captured bowel urgency as a rigorous patient-reported outcome, while INSPIRE focused on traditional clinical and endoscopic endpoints.
Efficacy Comparison
No head-to-head trial has directly compared Skyrizi with Omvoh in UC. Indirect comparisons suggest similar clinical remission rates between the two drugs. For skyrizi vs omvoh UC effectiveness, current data does not establish a clear winner, and decision-making often defaults to dosing preference, urgency profile, and insurance coverage.
Bowel Urgency Outcomes
A distinctive feature of Omvoh's data is bowel urgency improvement. LUCENT showed significant improvement in urgency numerical rating scale scores at both induction and maintenance, which matters to patients whose daily life is disrupted by sudden urgency episodes. Skyrizi's INSPIRE and COMMAND trials did not capture bowel urgency with the same rigor. For UC patients whose primary quality-of-life concern is urgency rather than stool frequency, Omvoh's outcome profile is distinctive in a way that may inform the choice.
Onset of Action
Both drugs produce clinically meaningful UC response by week 12. The induction endpoints are comparable. For patients in active flare who need rapid improvement, the two drugs are comparable in practice, and individual response variability often matters more than small differences in trial design.
Administration and Dosing
Skyrizi for UC uses IV induction at weeks 0, 4, and 8 (1200 mg per infusion), followed by subcutaneous maintenance of 180 mg or 360 mg every 8 weeks. Omvoh for UC uses IV induction at 300 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 200 mg every 4 weeks, per Lilly's Omvoh prescribing information. For UC patients comparing long-term dosing frequency, Skyrizi's every-8-week SC maintenance is less frequent than Omvoh's every-4-week SC maintenance. Induction infusion volumes differ, with Skyrizi's 1200 mg IV requiring longer infusion time than Omvoh's 300 mg IV.
Safety Profiles
Both drugs have favorable safety profiles consistent with IL-23 p19 class effects. Long-term data from each drug's other indications supports low rates of serious infection and malignancy. For skyrizi vs omvoh side effects, common adverse events on both drugs include upper respiratory infections, injection site reactions, and headache. Neither drug has a black-box warning for lymphoma or other class-level serious adverse events seen with anti-TNFs. TB and hepatitis B screening is recommended before starting either drug.
Anti-TNF Experienced Patients
Both Skyrizi's INSPIRE and Omvoh's LUCENT-1 included biologic-experienced UC patients, with meaningful response rates in each population. For UC patients who have already failed an anti-TNF, either drug is a reasonable mechanism-switch option. Your GI will weigh prior biologic exposure pattern, current disease severity, and comorbidities when making the recommendation.
Cost and Access
Both Skyrizi and Omvoh are branded biologics without biosimilar competition. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in UC. Manufacturer copay assistance programs exist for commercially insured patients on both drugs.
Choosing With Your GI
For a UC patient deciding between Skyrizi and Omvoh, Skyrizi tends to win on less frequent SC maintenance (every 8 weeks vs every 4 weeks). Omvoh tends to win on distinctive bowel urgency outcomes from LUCENT and being the first IL-23 p19-selective biologic approved for UC. Ask your GI which drug they have the most experience with, how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency episodes, blood, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.